Last update 15 Jul 2025

ESG-406

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
ESG 406, ESG406
Target-
Action-
Mechanism-
Therapeutic Areas
Neoplasms
Active Indication
Solid tumorAdvanced Malignant Solid Neoplasm
Inactive Indication-
Originator Organization
Shanghai Escugen Biotechnology Co., Ltd.Shanghai Escugen Biotechnology Co., Ltd.
Active Organization
Shanghai Escugen Biotechnology Co., Ltd.Shanghai Escugen Biotechnology Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
login
or
view full example data
Boost your research with our ADC technology data.

Related

1
Clinical Trials associated with ESG-406
NCT06979674
/ Not yet recruitingPhase 1
An Open-Label, Multiple Dose, Dose Escalation and Cohort Expansion Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of ESG406 in Subjects With Locally Advanced/Metastatic Solid Tumors
100 Clinical Results associated with ESG-406
Login to view more data
100 Translational Medicine associated with ESG-406
Login to view more data
100 Patents (Medical) associated with ESG-406
Login to view more data
100 Deals associated with ESG-406
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Solid tumorPhase 1
China
Shanghai Escugen Biotechnology Co., Ltd.Shanghai Escugen Biotechnology Co., Ltd.
09 May 2025
Advanced Malignant Solid NeoplasmIND Approval
China
Shanghai Escugen Biotechnology Co., Ltd.Shanghai Escugen Biotechnology Co., Ltd.
23 Apr 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free